Jump Financial LLC purchased a new stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 13,400 shares of the company’s stock, valued at approximately $381,000.
Other hedge funds also recently modified their holdings of the company. JPMorgan Chase & Co. increased its position in shares of PROCEPT BioRobotics by 18.2% during the first quarter. JPMorgan Chase & Co. now owns 5,353 shares of the company’s stock valued at $188,000 after purchasing an additional 825 shares during the period. Bank of New York Mellon Corp raised its stake in shares of PROCEPT BioRobotics by 59.8% in the 1st quarter. Bank of New York Mellon Corp now owns 22,079 shares of the company’s stock valued at $772,000 after buying an additional 8,265 shares in the last quarter. MetLife Investment Management LLC bought a new position in shares of PROCEPT BioRobotics during the 1st quarter worth about $175,000. Rhumbline Advisers bought a new position in shares of PROCEPT BioRobotics during the 1st quarter worth about $253,000. Finally, BlackRock Inc. boosted its position in shares of PROCEPT BioRobotics by 9.8% during the 1st quarter. BlackRock Inc. now owns 352,791 shares of the company’s stock valued at $12,344,000 after acquiring an additional 31,486 shares in the last quarter. Institutional investors own 73.18% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on the stock. William Blair initiated coverage on shares of PROCEPT BioRobotics in a research report on Wednesday, May 31st. They issued an “outperform” rating for the company. Truist Financial cut their target price on PROCEPT BioRobotics from $54.00 to $49.00 in a research report on Friday, April 28th. Finally, Bank of America lowered their price target on PROCEPT BioRobotics from $52.00 to $44.00 in a research report on Friday, April 28th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $45.60.
PROCEPT BioRobotics Stock Performance
NASDAQ:PRCT opened at $34.73 on Tuesday. PROCEPT BioRobotics Co. has a 1 year low of $25.29 and a 1 year high of $52.40. The firm has a 50 day moving average of $35.21 and a 200-day moving average of $34.33. The company has a current ratio of 6.40, a quick ratio of 5.21 and a debt-to-equity ratio of 0.34.
Insider Buying and Selling at PROCEPT BioRobotics
In other news, CFO Kevin Waters sold 22,631 shares of the stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $35.12, for a total transaction of $794,800.72. Following the sale, the chief financial officer now owns 33,523 shares in the company, valued at $1,177,327.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Kevin Waters sold 22,631 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $35.12, for a total transaction of $794,800.72. Following the transaction, the chief financial officer now directly owns 33,523 shares in the company, valued at $1,177,327.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Alaleh Nouri sold 7,903 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $40.00, for a total transaction of $316,120.00. Following the completion of the sale, the executive vice president now directly owns 46,933 shares of the company’s stock, valued at approximately $1,877,320. The disclosure for this sale can be found here. Corporate insiders own 19.60% of the company’s stock.
About PROCEPT BioRobotics
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).
Featured Stories
- Five stocks we like better than PROCEPT BioRobotics
- Where to Find Earnings Call Transcripts
- 8 Best Meme Stocks to Buy Now
- Consumer Staples Stocks, Explained
- Is Now The Time To Buy XLF Financial ETF?
- What’s a Sound Playbook for Investors During Election Years?
- Three Ways To Play The Rise In Oil Prices
Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.
